Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR
Benzinga Newsdesk 9 months ago
News
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR").